Send to

Choose Destination
See comment in PubMed Commons below
Cancer Invest. 2015;33(10):526-31. doi: 10.3109/07357907.2015.1080832. Epub 2015 Nov 4.

Mitogen-Activated Protein Kinase Pathway: Genetic Analysis of 95 Adrenocortical Tumors.

Author information

  • 1a Division of Endocrinology, Department of Medicine (DIMED) , University of Padua , Padua , Italy.
  • 2b Department of Molecular Medicine , University of Padua , Padua , Italy.
  • 3c Division of Minimally Invasive Endocrine Surgery, Department of Surgery, Oncology and Gastroenterology , University of Padua , Padua , Italy.
  • 4d Division of Pathology and Cytopathology, Department of Medicine (DIMED) , University of Padua , Padua , Italy.


Mitogen-activated protein kinase (MAPK) pathway is often deregulated in adrenocortical tumors (ACT) but with no concrete data confirming alteration rate. The objective of this study was to evaluate genetic alterations in key components of MAPK pathway. We found one BRAF mutation (p.V600E) and four HRAS silent mutations. No alteration was found in NRAS, KRAS, EGFR genes. The patient carrying BRAF mutation was further characterized by investigating his biomolecular and clinico-pathological findings. Therefore, even if MAPK signaling is activated in ACT, our results suggest that genetic alterations do not seem to represent a frequent mechanism of ACT tumorigenesis.


Adrenocortical carcinomas; Adrenocortical tumors; BRAF; MAPK signaling pathway; RAS

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center